Graydon Harker
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 10%
Papers in
- Oncology 8
- HER2/EGFR in Cancer Research 3
- Cancer Treatment and Pharmacology 2
- Lung Cancer Research Studies 1
-
- Head and Neck Cancer Studies 2
- Co-authors
- Paul Joseph Hesketh (2 shared papers)David R. Gandara (2 shared papers)Matti Aapro (1 shared paper)Steven M. Grunberg (1 shared paper)Celeste M Lindley (1 shared paper)THOMAS M. BECK (1 shared paper)Mark G. Kris (1 shared paper)John D. Hainsworth (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Clinical Breast Cancer (3 papers)Lung Cancer (2 papers)Otolaryngology (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United States
In The Last Decade
Graydon Harker
13 papers receiving 1.6k citations
Graydon Harker's Hit Papers
Peers
Comparison fields: 5 of 83
- Oncology 874
- Cancer Research 185
- Surgery 526
- Pulmonary and Respiratory Medicine 300
- Genetics 61
Countries citing papers authored by Graydon Harker
This map shows the geographic impact of Graydon Harker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graydon Harker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graydon Harker more than expected).
Fields of papers citing papers by Graydon Harker
This network shows the impact of papers produced by Graydon Harker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graydon Harker. The network helps show where Graydon Harker may publish in the future.
Co-authors
The 25 scholars most cited alongside Graydon Harker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2016 | 455 |
| 2 | 1997 | 440 | |
| 3 | 2003 | 255 | |
| 4 | 2006 | 253 | |
| 5 | 1991 | 134 | |
| 6 | 2011 | 59 | |
| 7 | 2019 | 24 | |
| 8 | 2012 | 19 | |
| 9 | 1989 | 17 | |
| 10 | 1987 | 16 | |
| 11 | 2011 | 16 | |
| 12 | 2012 | 7 | |
| 13 | 1990 | 2 |
About Graydon Harker
Graydon Harker is a scholar working on Oncology, Otorhinolaryngology, Surgery, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health, having authored 13 papers that have together received 1.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), Head and Neck Cancer Studies (2 papers), Nausea and vomiting management (2 papers), Cancer Treatment and Pharmacology (2 papers), Salivary Gland Tumors Diagnosis and Treatment (1 paper), Lung Cancer Research Studies (1 paper), Neuroendocrine Tumor Research Advances (1 paper) and Brain Metastases and Treatment (1 paper). The work is most often cited by research in Oncology (874 citations), Cancer Research (185 citations), Surgery (526 citations), Pulmonary and Respiratory Medicine (300 citations) and Genetics (61 citations). Graydon Harker has collaborated with scholars based in United States. Frequent co-authors include Paul Joseph Hesketh, David R. Gandara, Matti Aapro, Steven M. Grunberg, Celeste M Lindley, THOMAS M. BECK, Mark G. Kris, John D. Hainsworth, Charles S. Fuchs and David A. Rinaldi. Their work appears in journals such as Journal of Clinical Oncology, Clinical Breast Cancer, Lung Cancer, Otolaryngology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.